Brief: Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration
27/03/2025 20:02
March 27 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) BY THE UNITED STATES (U.S.) FOOD AND DRUG ADMINISTRATION Source text: ID:nGNX27zmrW Further company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta